Seagen (Seagen) Price-to-Operating-Cash-Flow : (As of Apr. 26, 2024)

View and export this data going back to 2001. Start your Free Trial

What is Seagen Price-to-Operating-Cash-Flow?

As of today (2024-04-26), Seagen's share price is $228.74. Seagen's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.89. Hence, Seagen's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Seagen's Price-to-Operating-Cash-Flow or its related term are showing as below:

During the past 13 years, Seagen's highest Price-to-Operating-Cash-Flow Ratio was 38.30. The lowest was 32.36. And the median was 34.58.

SGEN's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.725
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Seagen's Cash Flow from Operations per share for the three months ended in Sep. 2023 was $-0.19. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 was $-2.89.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was -36.60% per year.

During the past 13 years, Seagen's highest 3-Year average Operating Cash Flow per Share Growth Rate was 22.40% per year. The lowest was -391.40% per year. And the median was -12.30% per year.

Seagen Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Seagen's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seagen Price-to-Operating-Cash-Flow Chart

Seagen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Price-to-Operating-Cash-Flow

Get a 7-Day Free Trial

37.27

Seagen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Seagen's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Seagen's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seagen's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seagen's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Seagen's Price-to-Operating-Cash-Flow falls into.

Seagen Price-to-Operating-Cash-Flow Calculation

Seagen's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	228.74	/	-2.887
	=

Seagen's Share Price of today is $228.74.
Seagen's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.89.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Seagen Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Seagen's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Seagen (Seagen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seagen Inc (NAS:SGEN) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

N/A

Address

21823 - 30th Drive South East, Bothell, WA, USA, 98021

Website

https://www.seagen.com

Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.

Executives

David R Epstein	director, officer: Chief Executive Officer	INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Vaughn B Himes	officer: See Remarks	C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Charles R Romp	officer: EVP, Commercial	21823 30TH DRIVE SE, BOTHELL WA 98021
Roger D Dansey	officer: See Remarks	21823 30TH DRIVE SE, BOTHELL WA 98021
Jean I Liu	officer: GC & EVP, Legal Affairs	21823 30TH DRIVE SE, BOTHELL WA 98021
Todd E Simpson	officer: Chief Financial Officer
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
David W Gryska	director	749 N MARY AVE, SUNNYVALE CA 94085
Sandra M Swain	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Clay B Siegall	director, officer: President and CEO	21823 30TH DR SE, BOTHELL WA 98021
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014